Do Immunotherapy Allergy Shots Work? Where SCIT Fits the Landscape

SCIT and SLIT produce comparable efficacy for allergic rhinitis based on network meta-analyses — the indirect comparison SMDs for symptom and medication scores do not show a significant difference for single allergen-matched products. SCIT retains advantages for polysensitized patients needing multi-allergen custom mixes, since SLIT tablets are FDA-approved for only four allergens. SLIT has dramatically better safety — 83% lower adverse event rates in pediatric meta-analysis (Wang et al., Front Pharmacol 2024), no confirmed fatalities, and daily home administration eliminates the weekly clinic visit burden that causes 50-70% of SCIT patients to drop out before completing treatment. The current clinical consensus favors SLIT tablets for FDA-approved single-allergen indications and SCIT for polysensitized patients.

Venom immunotherapy (VIT) achieves the highest efficacy of any allergy immunotherapy modality — 98% protection against life-threatening sting reactions, per Golden et al. (JACI 2011), making it one of the most successful treatments in all of medicine for patients with Hymenoptera sting anaphylaxis. For aeroallergen allergy (rhinitis, asthma), SCIT and FDA-approved SLIT tablets are functionally equivalent based on network meta-analyses. OIT (oral immunotherapy) for peanut allergy achieved desensitization in about two-thirds of participants in the PALISADE trial but requires ongoing maintenance dosing — unlike SCIT and SLIT, which can produce sustained unresponsiveness after stopping. No single 'most effective' modality applies across all allergy types.

Yes, in terms of long-term outcomes SCIT outperforms antihistamines and nasal steroids in a fundamental way: disease modification. Antihistamines and nasal steroids control symptoms only while taken and produce zero lasting immune change. SCIT produces clinical remission that persists for 3 to 12 years after stopping treatment, prevents new allergen sensitizations, and reduces asthma development in children. In direct efficacy comparisons, Matricardi et al. found SCIT's short-term symptom reduction comparable to intranasal mometasone and significantly superior to antihistamines and leukotriene antagonists. The unique long-term value, however, is not available from pharmacotherapy at any dose or duration.

The World Allergy Organization (WAO) and World Health Organization position, outlined in Canonica et al. (WAO Journal 2014) and WHO position papers, is that subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are the only disease-modifying treatments for IgE-mediated allergic disease. Both receive Grade A evidence endorsement for allergic rhinitis and asthma. The WHO distinguishes these from all other allergy treatments (antihistamines, corticosteroids, biologics) by their ability to modify the underlying allergic disease course, not merely suppress symptoms. SCIT is recommended as first-line therapy alongside or instead of pharmacotherapy for patients with moderate-to-severe allergic rhinitis.

Yes — the immunotherapy field is actively developing modalities beyond conventional SCIT. Intralymphatic immunotherapy (ILIT) delivers allergen directly into lymph nodes, requiring only 3 injections versus 60-plus for SCIT, with promising early data from Senti et al. (PNAS 2008). Epicutaneous immunotherapy (EPIT, Viaskin patch) delivers allergen through intact skin and is in Phase III trials for peanut allergy. Peptide immunotherapy uses short allergen peptide fragments designed to minimize systemic reaction risk; Cat-SPIRE (Circassia) showed promising early results but failed Phase III in 2016. Biologics like omalizumab (anti-IgE) complement rather than replace immunotherapy and are increasingly used to enable safer accelerated SCIT build-up in highly reactive patients.

Combining different immunotherapy modalities concurrently is generally not recommended or studied for the same allergen class. Omalizumab (anti-IgE biologic) is an exception — it has been used concurrently with SCIT to reduce systemic reaction risk during rush build-up protocols, with Casale et al. (JACI 2006) showing a 5-fold reduction in anaphylaxis during ragweed rush with 9 weeks of omalizumab pretreatment. For patients already on SCIT who need additional allergen coverage, adding allergens to an existing SCIT vial is possible if the allergist determines dose adequacy for each component can be maintained. Sequential treatment (completing SCIT then transitioning to SLIT for maintenance) is an area of investigation but not yet standard practice.